Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts

Neurobiology of Aging

Volumn 36, Issue 8, 2015, Pages 2333-2339

  Resnick, Susan M ^a   Bilgel, Murat ^a,b   Moghekar, Abhay ^c   An, Yang ^a   Cai, Qing ^d   Wang, Mei Cheng ^d   Thambisetty, Madhav ^a   Prince, Jerry L ^b,c,e   Zhou, Yun ^c   Soldan, Anja ^c   Wong, Dean F ^c   O'Brien, Richard J ^c   Ferrucci, Luigi ^a   Albert, Marilyn S ^c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b Johns Hopkins University   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e Johns Hopkins University   (United States)

Author keywords

Apolipoprotein E genotype; Biomarkers; CSF A 1 42; Longitudinal; PET amyloid imaging

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID BETA-PROTEIN (1-42); ANILINE DERIVATIVE; CARBON; PEPTIDE FRAGMENT; RADIOPHARMACEUTICAL AGENT; THIAZOLE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; APOE GENE; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; LONGITUDINAL STUDY; MALE; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; BRAIN; CEREBROSPINAL FLUID; GENETICS; METABOLISM; MIDDLE AGED; VERY ELDERLY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEINS E; BRAIN; CARBON RADIOISOTOPES; COHORT STUDIES; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 84952638856     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.04.001     Document Type: Article

References (30)

1. Albert M., Soldan A., Gottesman R., McKhann G., Sacktor N., Farrington L., Grega M., Turner R.S., Lu Y., Li S., Wang M.-C., Selnes O. Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype. Curr Alzheimer Res 2014, 11:773-784.
2. Bracco L., Piccini C., Baccini M., Bessi V., Biancucci F., Nacmias B., Bagnoli S., Sorbi S. Pattern and progression of cognitive decline in Alzheimer's disease: role of premorbid intelligence and ApoE genotype. Dement Geriatr Cogn Disord 2007, 24:483-491.
3. Daly E., Zaitchik D., Copeland M., Schmahmann J., Gunther J., Albert M. Predicting conversion to Alzheimer disease using standardized clinical information. Arch. Neurol. 2000, 57:675-680.
4. Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition, DSM-IV 1994, American Psychiatric Association, Washington, D.C.
5. Driscoll I., Resnick S.M., Troncoso J.C., An Y., O'Brien R., Zonderman A.B. Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann. Neurol. 2006, 60:688-695.
6. Fleisher A.S., Chen K., Liu X., Ayutyanont N., Roontiva A., Thiyyagura P., Protas H., Joshi A.D., Sabbagh M., Sadowsky C.H., Sperling R.A., Clark C.M., Mintun M.A., Pontecorvo M.J., Coleman R.E., Doraiswamy P.M., Johnson K.A., Carpenter A.P., Skovronsky D.M., Reiman E.M. Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging 2013, 34:1-12.
7. Fouquet M., Besson F.L., Gonneaud J., La Joie R., Chetelat G. Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan. Neuropsychol. Rev. 2014, 24:290-299.
8. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 1990, 31:545-548.
9. Johnson K.A., Sperling R.A., Gidicsin C.M., Carmasin J.S., Maye J.E., Coleman R.E., Reiman E.M., Sabbagh M.N., Sadowsky C.H., Fleisher A.S., Murali Doraiswamy P., Carpenter A.P., Clark C.M., Joshi A.D., Lu M., Grundman M., Mintun M.A., Pontecorvo M.J., Skovronsky D.M. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013, 9(5 Suppl):S72-83.
10. Kawas C., Gray S., Brookmeyer R., Fozard J., Zonderman A. Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 2000, 54:2072-2077.
11. Khachaturian A.S., Corcoran C.D., Mayer L.S., Zandi P.P., Breitner J.C. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the Cache County Study. Arch. Gen. Psychiatry 2004, 61:518-524. Cache County Study Investigators.
12. Martins C.A., Oulhaj A., de Jager C.A., Williams J.H. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 2005, 65:1888-1893.
13. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.K., van der Flier W.M., Blankenstein M.A., Ewers M., Rich K., Kaiser E., Verbeek M., Tsolaki M., Mulugeta E., Rosen E., Aarsland D., Visser P.J., Schroder J., Marcusson J., de Leon M., Hampel H., Scheltens P., Pirttila T., Wallin A., Jonhagen M.E., Minthon L., Winblad B., Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393.
14. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
15. Moghekar A., Li S., Lu Y., Li M., Wang M.C., Albert M., O'Brien R. CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology 2013, 81:1753-1758.
16. Morris J.C. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
17. Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., Mintun M.A. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010, 67:122-131.
18. Peskind E.R., Li G., Shofer J., Quinn J.F., Kaye J.A., Clark C.M., Farlow M.R., DeCarli C., Raskind M.A., Schellenberg G.D., Lee V.M., Galasko D.R. Age and apolipoprotein E×4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 2006, 63:936-939.
19. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B., Alexander G.E., Klunk W.E., Mathis C.A., Price J.C., Aizenstein H.J., DeKosky S.T., Caselli R.J. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U. S. A 2009, 106:6820-6825.
20. Resnick S.M., Goldszal A.F., Davatzikos C., Golski S., Kraut M.A., Metter E.J., Bryan R.N., Zonderman A.B. One-year age changes in MRI brain volumes in older adults. Cereb Cortex 2000, 10:464-472.
21. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V.L. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010, 31:1275-1283.
22. Slooter A.J., Houwing-Duistermaat J.J., van Harskamp F., Cruts M., Van Broeckhoven C., Breteler M.M., Hofman A., Stijnen T., van Duijn C.M. Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study. J Neurol 1999, 246:304-308.
23. Sojkova J., Zhou Y., An Y., Kraut M.A., Ferrucci L., Wong D.F., Resnick S.M. Longitudinal patterns of beta-amyloid deposition in nondemented older adults. Arch Neurol 2011, 68:644-649.
24. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
25. Thambisetty M., Tripaldi R., Riddoch-Contreras J., Hye A., An Y., Campbell J., Sojkova J., Kinsey A., Lynham S., Zhou Y., Ferrucci L., Wong D.F., Lovestone S., Resnick S.M. Proteome-based plasma markers of brain amyloid-beta deposition in non-demented older individuals. J Alzheimers Dis 2010, 22:1099-1109.
26. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15:273-289.
27. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., Ames D., Rowe C.C., Masters C.L. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. The Lancet Neurology 2013, 12:357-367.
28. Villemagne V.L., Pike K.E., Chetelat G., Ellis K.A., Mulligan R.S., Bourgeat P., Ackermann U., Jones G., Szoeke C., Salvado O., Martins R., O'Keefe G., Mathis C.A., Klunk W.E., Ames D., Masters C.L., Rowe C.C. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011, 69:181-192.
29. Vlassenko A.G., Mintun M.A., Xiong C., Sheline Y.I., Goate A.M., Benzinger T.L., Morris J.C. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol 2011, 70:857-861.
30. Zhou Y., Resnick S.M., Ye W., Fan H., Holt D.P., Klunk W.E., Mathis C.A., Dannals R., Wong D.F. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. Neuroimage 2007, 36:298-312.